NCT02488967.

Study name	Doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin in treating patients with triple‐negative breast cancer
Methods	Accrual: recruiting Accrual target: 782 Multicentre, phase 3 RCT Trial is being conducted in USA Blinding: open‐label study
Participants	People with node positive or high‐risk node negative triple negative breast cancer Adjuvant or neoadjuvant: adjuvant
Interventions	Arm 1: intervention: doxorubicin then paclitaxel on days 1, 8 and 15 and carboplatin on day 1 every 3 weeks for 4 cycles Arm 2: comparator: doxorubicin and cyclophosphamide on day 3 every 2 weeks for 4 cycles, followed by paclitaxel day 1 weekly for 12 weeks
Outcomes	Primary Disease‐free survival Secondary Breast cancer‐free survival Distant recurrence‐free interval Adverse events Overall survival Recurrence‐free interval
Starting date	Planned start date: July 2015 Estimated completion date: November 2023
Contact information	Contact: Vicente Valero (askmdanderson@mdanderson.org)
Notes	Trial registration link: clinicaltrials.gov/ct2/show/NCT02488967 Trial sponsor: NRG Oncology Funding considerations: not provided in trial record